In Silico Strategies for Prospective Drug Repositionings
The discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new a...
Saved in:
Other Authors: | , , , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_96611 | ||
005 | 20230202 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230202s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-6133-2 | ||
020 | |a 9783036561349 | ||
020 | |a 9783036561332 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-6133-2 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
072 | 7 | |a KNDP |2 bicssc | |
100 | 1 | |a Udrescu, Lucreția |4 edt | |
700 | 1 | |a Kurunczi, Ludovic |4 edt | |
700 | 1 | |a Bogdan, Paul |4 edt | |
700 | 1 | |a Udrescu, Mihai |4 edt | |
700 | 1 | |a Udrescu, Lucreția |4 oth | |
700 | 1 | |a Kurunczi, Ludovic |4 oth | |
700 | 1 | |a Bogdan, Paul |4 oth | |
700 | 1 | |a Udrescu, Mihai |4 oth | |
245 | 1 | 0 | |a In Silico Strategies for Prospective Drug Repositionings |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (288 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a The discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new anticancer drugs, new antivirals).Within this framework, drug repositioning-finding new pharmacodynamic properties for already approved drugs-becomes a worthy drug discovery strategy.Recent drug discovery techniques combine traditional tools with in silico strategies to identify previously unaccounted properties for drugs already in use. Indeed, big data exploration techniques capitalize on the ever-growing knowledge of drugs' structural and physicochemical properties, drug-target and drug-drug interactions, advances in human biochemistry, and the latest molecular and cellular biology discoveries.Following this new and exciting trend, this book is a collection of papers introducing innovative computational methods to identify potential candidates for drug repositioning. Thus, the papers in the Special Issue In Silico Strategies for Prospective Drug Repositionings introduce a wide array of in silico strategies such as complex network analysis, big data, machine learning, molecular docking, molecular dynamics simulation, and QSAR; these strategies target diverse diseases and medical conditions: COVID-19 and post-COVID-19 pulmonary fibrosis, non-small lung cancer, multiple sclerosis, toxoplasmosis, psychiatric disorders, or skin conditions. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
650 | 7 | |a Pharmaceutical industries |2 bicssc | |
653 | |a COVID-19 | ||
653 | |a drug repurposing | ||
653 | |a topological data analysis | ||
653 | |a persistent Betti function | ||
653 | |a SARS-CoV-2 | ||
653 | |a network-based pharmacology | ||
653 | |a combination therapy | ||
653 | |a nucleoside GS-441524 | ||
653 | |a fluoxetine | ||
653 | |a synergy | ||
653 | |a antidepressant | ||
653 | |a natural compounds | ||
653 | |a QSAR | ||
653 | |a molecular docking | ||
653 | |a drug repositioning | ||
653 | |a UK Biobank | ||
653 | |a vaccine | ||
653 | |a LC-2/ad cell line | ||
653 | |a drug discovery | ||
653 | |a docking | ||
653 | |a MM-GBSA calculation | ||
653 | |a molecular dynamics | ||
653 | |a cytotoxicity assay | ||
653 | |a GWAS | ||
653 | |a multiple sclerosis | ||
653 | |a oxidative stress | ||
653 | |a repurposing | ||
653 | |a ADME-Tox | ||
653 | |a bioinformatics | ||
653 | |a complex network analysis | ||
653 | |a modularity clustering | ||
653 | |a ATC code | ||
653 | |a hidradenitis suppurativa | ||
653 | |a acne inversa | ||
653 | |a transcriptome | ||
653 | |a proteome | ||
653 | |a comorbid disorder | ||
653 | |a biomarker | ||
653 | |a signaling pathway | ||
653 | |a druggable gene | ||
653 | |a drug-repositioning | ||
653 | |a MEK inhibitor | ||
653 | |a MM/GBSA | ||
653 | |a Glide docking | ||
653 | |a MD simulation | ||
653 | |a MM/PBSA | ||
653 | |a single-cell RNA sequencing | ||
653 | |a pulmonary fibrosis | ||
653 | |a biological networks | ||
653 | |a p38α MAPK | ||
653 | |a allosteric inhibitors | ||
653 | |a in silico screening | ||
653 | |a computer-aided drug discovery | ||
653 | |a network analysis | ||
653 | |a psychiatric disorders | ||
653 | |a medications | ||
653 | |a psychiatry | ||
653 | |a mental disorders | ||
653 | |a toxoplasmosis | ||
653 | |a Toxoplasma gondii | ||
653 | |a in vitro screening | ||
653 | |a drug targets | ||
653 | |a drug-disease interaction | ||
653 | |a target-disease interaction | ||
653 | |a DPP4 inhibitors | ||
653 | |a lipid rafts | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6556 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/96611 |7 0 |z DOAB: description of the publication |